The Real-world Study of Rimegepant Treatment in Female Migraine Patients of China

Sponsor
The First Affiliated Hospital of Soochow University
Study ID
NCT06728345
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Rimegepant — DRUG
    Female migraine patients take Rimegepant (75mg QOD) as their regular prophylactic treatment of migraine for 12 weeks

Study Details

The goal of this observational study is to learn about the effects and safety of Rimegepant in women, especially young and middle-aged women, who take Rimegepant to treat their migraine in the real world. Participants already taking Rimegepant (75mg QOD) as their regular preventive treatment of migraine for 12 weeks will be evaluated as the followings : 1. To evaluate the change from baseline in the mean number of migraine days per month during weeks 1-12 2. To evaluate the number of participants that have least a 50% reduction from baseline in the mean number of migraine days per month during weeks 1-12

Key Dates

Start date
Dec 1, 2024
Status verified
Dec 2024
Primary completion
Jun 30, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: female migraine patients who recevie Rimegepant as prophylactic treatment

Primary Outcome Measure

Mean change from the baseline in the number of migraine days per month over the entire treatment phase (Weeks 1-12) [ Time Frame: The treatment period is 12 weeks ]

Central Contacts

Related Studies